AAN 2022 poster: Associations between deflazacort versus prednisone/prednisolone and markers of disease progression in clinically important subgroups of patients with Duchenne muscular dystrophy
Presented at the 2022 AAN Annual Meeting in Seattle, USA, this poster shows results from a study investigating disease progression following treatment with different corticosteroids for Duchenne muscular dystrophy (DMD)
Learn about the study design and baseline characteristics of patients with DMD from 4 clinical trials, who were investigated in this research
Read more on the primary and secondary endpoints used to assess the effect of treatment with different corticosteroids
Find out about the clinical effect of different corticosteroids in patients with DMD, stratified by age, length of corticosteroid use, and stage of disease progression
Deflazacort is a corticosteroid indicated for the treatment of DMD in patients 2 years of age and older. PTC Therapeutics is the Marketing Authorization Holder for deflazacort in the US only. Registration conditions differ internationally, and prescribing information may vary depending on local approval in each country. The US Prescribing Information for deflazacort is available here. Please refer to your local country guidance for more information.
Some cookies are essential, others help us improve your experience by providing insights into how the website is used. Select one or more of the cookie types listed below, and then save your preferences. Refer to our Cookies Statement for more information.
Performance cookies, which help us measure the website’s performance and improve your experience. In using performance cookies we do not store any personal data, and only use the information collected through these cookies in aggregated and anonymised form.